Return to homepagePandemic Pact

Rational identification of SARS-CoV-2 replication inhibitors targeting multiple enzymes of the replication-transcription complex

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020

  • Funder

    Volkswagen Stiftung

  • Principal Investigator

    Prof Dr and Dr Birgit Strodel, Olujide Olubiyi

  • Research Location

    Germany

  • Lead Research Institution

    Forschungszentrum Jülich GmbH

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The project team will employ state-of-the-art computer-aided drug design techniques followed by experimental validation to identify inhibitors of the non-structural proteins composing the COVID-19 causing SARS-CoV-2 replication-transcription complex. With the focus on drug repurposing and usage of safe natural products, it is expected to find a combination of such compounds that will effectively stop SARS-CoV-2 replication and could thus be used as a therapeutic approach to treat COVID-19. This would help lifting the multiple burdens the world currently faces during the COVID-19 pandemic.